FGFR4 as target in cancer treatment
WO2025036876A3 Publication Date: 2025-03-27ONA THERAPEUTICS SL +5
8 Cites 0 Cited by
Patent Information
- Application Number
- PCT/EP2024/072737
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-08-16
- Filing Date
- 2024-08-12
- Publication Date
- 2025-03-27
AI Technical Summary
Technical Problem
Current treatments for hormone receptor-positive (HR+) breast cancer, particularly those involving CDK4/6 inhibitors, face challenges due to the development of resistance mechanisms, necessitating the identification of new therapeutic approaches.
Method used
The use of FGFR4 as a predictive biomarker to determine the effectiveness of CDK4/6 inhibitor therapy, combined with the development of FGFR4-binding molecules or inhibitors, such as antibody-drug conjugates (ADCs), to target and overcome resistance in cancer treatment.
Benefits of technology
FGFR4 expression levels can predict response to CDK4/6 inhibitor therapy, and targeting FGFR4 with specific ADCs can restore sensitivity to CDK4/6 inhibitors and improve treatment outcomes for HR+ breast cancer patients.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention provides new therapeutic approaches for the treatment or prevention of FGFR4-expressing cancers, including those resistant to other therapies.
Need to check novelty before this filing date? Find Prior Art